Alison Axtman

Alison Axtman

SGC UNC

Axtman

Alison Axtman

(216) 470-7201

Biography

Alison Axtman is a synthetic medicinal chemist with more than 10 years of research experience working at the interface of chemical and biology. Alison earned her PhD in Medicinal Chemistry at the University of Kansas, and carried out her post-doctoral training in the Department of Chemistry at Stanford University. Alison’s research has focused on the synthesis of small molecules that selectively modulate proteins implicated in disease-propagating pathways. As a member of the GSK Chemical Biology department, she led a program to understand the molecular basis of immune modulation by a class of natural products and developed analogs with improved drug properties. Alison is currently a Research Assistant Professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Alison can be most often found at the gym preparing for the next CrossFit or GRID competition with her teammates.

2024

Targeting Na(v)1.7 and Na(v)1.8 with a PIKfyve inhibitor to reverse inflammatory and neuropathic pain.

Rodríguez-Palma EJ, Loya-Lopez S, Min SM, Calderon-Rivera A, Gomez K, Khanna R, Axtman AD

Neurobiol Pain. 2024-12-25 . 17:100174 .doi: 10.1016/j.ynpai.2024.100174

PMID: 39720155

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, Havener TM, Sanders MK, Brown JW, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

Molecules. 2024-9-14 . 29(17): .doi: 10.3390/molecules29174158

PMID: 39275006

Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.

Bashore FM, Min SM, Chen X, Howell S, Rinderle CH, Morel G, Silvaroli JA, Wells CI, Bunnell BA, Drewry DH, Pabla NS, Ultanir SK, Bullock AN, Axtman AD

ACS Med Chem Lett. 2024-8-8 . 15(8):1325-1333 .doi: 10.1021/acsmedchemlett.4c00219

PMID: 39140040

Illumination of understudied ciliary kinases.

Flax RG, Rosston P, Rocha C, Anderson B, Capener JL, Durcan TM, Drewry DH, Prinos P, Axtman AD

Front Mol Biosci. 11.07.2024. 11:1352781 .doi: 10.3389/fmolb.2024.1352781

PMID: 38523660

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM.

Bashore FM, Katis VL, Du Y, Sikdar A, Wang D, Bradshaw WJ, Rygiel KA, Leisner TM, Chalk R, Mishra S, Williams CA, Gileadi O, Brennan PE, Wiley JC, Gockley J, Cary GA, Carter GW, Young JE, Pearce KH, Fu H, Axtman AD

PLoS One. 11.07.2024. 19(2):e0293548 .doi: 10.1371/journal.pone.0293548

PMID: 38359047

More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication.

Ong HW, Yang X, Smith JL, Dickmander RJ, Brown JW, Havener TM, Taft-Benz S, Howell S, Sanders MK, Capener JL, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

J Med Chem. 2024-7-3 . .doi: 10.1021/acs.jmedchem.4c00962

PMID: 38959455

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.

Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL

Eur J Med Chem. 2024-4-2 . 271:116357 .doi: 10.1016/j.ejmech.2024.116357

PMID: 38636130

Synthesis of 5-Benzylamino and 5-Alkylamino-Substituted Pyrimido[4,5-c]quinoline Derivatives as CSNK2A Inhibitors with Antiviral Activity.

Asressu KH, Smith JL, Dickmander RJ, Moorman NJ, Wellnitz J, Popov KI, Axtman AD, Willson TM

Pharmaceuticals (Basel). 2024-2-27 . 17(3): .doi: 10.3390/ph17030306

PMID: 38543092

2023

Fused Tetrahydroquinolines Are Interfering with Your Assay.

Bashore FM, Annor-Gyamfi J, Du Y, Katis V, Nwogbo F, Flax RG, Frye SV, Pearce KH, Fu H, Willson TM, Drewry DH, Axtman AD

J Med Chem. 2023-10-24 . .doi: 10.1021/acs.jmedchem.3c01277

PMID: 37874947

Optimization of 3-Cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A.

Yang X, Ong HW, Dickmander RJ, Smith JL, Brown JW, Tao W, Chang E, Moorman NJ, Axtman AD, Willson TM

ACS Omega. 2023-10-24 . 8(42):39546-39561 .doi: 10.1021/acsomega.3c05377

PMID: 37901516